


**AMENDMENTS TO THE CLAIMS**

1. **(Currently amended)** A bicyclo derivative represented by the following formula (1):



wherein R<sup>1</sup> is Mecarboxyl group; X is CH<sub>2</sub>, CHF, CF<sub>2</sub> or CHOH; and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

2-5. **(Cancelled)**

6. **(Previously presented)** A pharmaceutical product containing as an active ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.

7. **(Cancelled)**

8. **(Withdrawn)** A method for treating a mammal having a disease involving DPP-IV, which comprises administering a therapeutically effective amount of the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.

9. **(Withdrawn)** The method according to claim 8, wherein the disease involving DPP-IV is diabetes or associated diabetic complication.

10. **(New)** The bicyclo derivative according to claim 1, wherein the compound represented by the formula (1) is (2S,4S)-1-[[N-(4-carboxybicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile or a pharmaceutically acceptable salt thereof.